Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01259388 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of Lithium in Progressive Multiple Sclerosis
A Phase 1 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT01259388: Completed Phase 1 study, sponsored by VA Office of Research and Development.
NCT01259388 is a Phase 1 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01259388, a Phase 1 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether lithium carbonate is safe, well-tolerated, and effective at treating progressive forms of multiple sclerosis.
Interventions
- DRUG Lithium Carbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01259388
The ClinicalTrials.gov registry entry for NCT01259388 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lithium Carbonate is the first listed.
NCT01259388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01259388 about?
NCT01259388 is a clinical study titled "A Pilot Study of Lithium in Progressive Multiple Sclerosis". The purpose of this study is to determine whether lithium carbonate is safe, well-tolerated, and effective at treating progressive forms of multiple sclerosis.
What is the current status of trial NCT01259388?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2011-05. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01259388?
The interventions under investigation include: Lithium Carbonate (DRUG).
Who is sponsoring clinical trial NCT01259388?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.